文献速递肿瘤 PET/CT

口咽鳞状细胞癌患者治疗中期瘤内代谢异质性变化与结局相关

Mid-treatment changes in intra-tumoural metabolic heterogeneity correlate to outcomes in oropharyngeal squamous cell carcinoma patients.
PubMed 文献 · EJNMMI Res · 2025-04-01

本研究评估口咽鳞状细胞癌(OPSCC)患者治疗中期瘤内代谢异质性及FDG-PET/CT定量参数变化与疗效的关系。114例来自两个独立队列的患者在基线和治疗第3周行FDG-PET,测量SUVmax、SUVmean、MTV、TLG及AUC-CSH。ΔMTV(aHR 1.04;95%CI 1.03-1.06;p<0.001)和ΔAUC-CSH(aHR 0.96;95%CI 0.94-0.98;p=0.004)与LRRFS相关。

要点

  • 治疗中期瘤内代谢异质性下降(ΔAUC-CSH 24%)被观察到。
  • ΔMTV和ΔAUC-CSH与局部区域无复发生存(LRRFS)相关。
  • 用ΔAUC-CSH联合p16状态或ΔMTV分层,2年LRRFS组间差异显著(log rank p<0.001)。

核心结论

  • OPSCC治疗中期瘤内FDG-PET/CT异质性变化与治疗结局相关,可能有助于反应预测。
  • 这些发现提示在将来设计风险适应性临床试验方面具有潜在用途。

研究设计与样本

  • 研究纳入来自两个独立队列的114例口咽鳞状细胞癌患者。
  • 患者在基线和治疗中期(第3周)接受FDG-PET/CT检查。
  • 测量SUVmax、SUVmean、MTV和TLG,瘤内代谢异质性以累积SUV-体积直方图曲线下面积(AUC-CSH)量化。
  • 采用多变量Cox回归分析基线和影像特征相对变化(%∆)与LRRFS的相关性。
  • 利用∆AUC-CSH和已知预后特征将患者分为三个风险组,采用Kaplan-Meier分析比较。

主要发现

  • 中位随访39个月,18%的患者在2年时出现局部区域复发。
  • 治疗中期观察到异质性下降(∆AUC-CSH:24%)。
  • p16阳性与p16阴性患者之间,基线肿瘤异质性(AUC-CSH)无统计学显著差异(p=0.134),第3周变化亦无统计学显著差异(p=0.306)。
  • 基线影像特征与LRRFS无相关性。
  • ∆MTV(aHR 1.04;95%CI 1.03-1.06;p<0.001)和∆AUC-CSH(aHR 0.96;95%CI 0.94-0.98;p=0.004)与LRRFS相关。

关键数值与推荐

  • ∆MTV与LRRFS相关(aHR 1.04;95%CI 1.03-1.06;p<0.001)。
  • ∆AUC-CSH与LRRFS相关(aHR 0.96;95%CI 0.94-0.98;p=0.004)。
  • ∆AUC-CSH联合p16状态分层三组,2年LRRFS 94%、79%、17%(log rank p<0.001)。
  • ∆AUC-CSH联合∆MTV分层三组,2年LRRFS 93%、70%、17%(log rank p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated mid-treatment changes in intra-tumoural metabolic heterogeneity and quantitative FDG-PET/CT imaging parameters and correlated the changes with treatment outcomes in oropharyngeal squamous cell cancer (OPSCC) patients. 114 patients from two independent cohorts underwent baseline and mid-treatment (week 3) FDG-PET. Standardized uptake value maximum (SUVmax), standardized uptake value mean (SUVmean), metabolic tumour volume (MTV), and total lesional glycolysis (TLG) were measured. Intra-tumoural metabolic heterogeneity was quantified as the area under a cumulative SUV-volume histogram curve (AUC-CSH). Baseline and relative change (%∆) in imaging features were correlated to locoregional recurrence free survival (LRRFS) using multivariate Cox regression analysis. Patients were stratified into three risk groups utilising ∆AUC-CSH and known prognostic features, then compared using Kaplan-Meier analysis. RESULTS: Median follow up was 39 months. 18% of patients developed locoregional recurrence at 2 years. A decrease in heterogeneity (∆AUC-CSH: 24%) was observed mid-treatment. There was no statistically significant difference in tumour heterogeneity (AUC-CSH) at baseline (p = 0.134) and change at week 3 (p = 0.306) between p16 positive and p16 negative patients. Baseline imaging features did not correlate to LRRFS. However, ∆MTV (aHR 1.04; 95% CI 1.03-1.06; p < 0.001) and ∆AUC-CSH (aHR 0.96; 95% CI 0.94-0.98; p = 0.004) were correlated to LRRFS. Stratification using ∆AUC-CSH and p16 status into three groups showed significant differences in LRR (2 year LRRFS 94%, 79%, 17%; log rank p < 0.001). Stratification using ∆AUC-CSH and ∆MTV into three groups showed significant differences in LRR (2 year LRRFS 93%, 70%, 17%; log rank p < 0.001). CONCLUSION: Mid-treatment changes in intra-tumoural FDG-PET/CT heterogeneity correlated with treatment outcomes in OPSCC and may help with response prediction. These findings suggest potential utility in designing future risk adaptive clinical trials.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Trada Y, Lee MT, Jameson MG, et al. Mid-treatment changes in intra-tumoural metabolic heterogeneity correlate to outcomes in oropharyngeal squamous cell carcinoma patients. EJNMMI Res. 2025. PMID: 40167887. doi:10.1186/s13550-025-01226-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。